top of page

Flex-NK™ Engagers

(Multi-Specific NK Engager Antibodies)

Our fully owned, patented plug-and-play multi-specific antibody platform allows for the rapid development of multiple drug candidates. The platform has been initially validated by a pan-academic consortium and is currently further developed at our partner development and GMP manufacturing facility in Greater Boston, MA. 

We are developing a proprietary tri-functional format for enhanced efficacy. We are focused on NK engager bi-specific and multi-specific antibodies for the treatment of hematological cancers and solid tumors.


Cytovia is developing NKp46 multifunctional engagers with the potential for better disease control and better safety profile.

bottom of page